Senzer Pharmaceuticals has announced the launch of a new Critical Care Division for development of two inhaled anti-viral drugs for the treatment of COVID-19. The company did not specify which drugs it planned to develop but did say that the formulations would be delivered via MDI rather than with its SIDD (Systemic Inhaled Delivery Device), which is used for its inhaled cannabinoid products.
According to Senzer, the company is focused on repurposing currently approved drugs for the treatment of COVID-19 and is looking at two additional candidates in addition to the two included in its first effort.
Senzer Pharmaceuticals CEO Alex Hearn commented, “When the Covid pandemic struck we quickly realized that our expertise in respiratory pharmaceuticals had specific relevance. We have considerable formulation expertise within the team, as well as an understanding of the regulatory environment, and so are currently 100% focused on deploying all of our requisite skills to ensure we can develop and deliver novel investigational medicines for clinical trial use in the shortest possible time, in order to support the front line medical staff and their patients during this crisis.”
Read the Senzer press release.
